Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop ...

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ ... an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE). On Tuesday, based on data from those with estrogen ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

Pfizer and Arvinas have shared promising top-line results from a late-stage study of their investigational protein degrader vepdegestrant in a subset of breast cancer patients. The phase 3 VERITAC-2 ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...

Arvinas, Inc., a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases, and Pfizer Inc. announced positive topline ...